RNS Number:6237J
Arana Therapeutics Limited
11 December 2007



For Immediate Release                                           11 December 2007
                                                                           



                             ARANA THERAPEUTICS LTD


                    ARANA ANNOUNCES RESIGNATION OF DIRECTOR



Arana Therapeutics Limited (ASX: AAH, AIM: AAHx) the Australian
biopharmaceutical company focused on the development of antibody and peptide
products for the treatment of inflammatory diseases and cancer, today announced
that Greg Bundy has accepted a full time executive role with San Franciso based
BTIG LLC, one of America's largest electronic institutional trading firms. The
time and travel commitments of this role are such that he will not be able to
devote significant time to other activities. He has therefore resigned from the
Arana Therapeutics board with immediate effect.


Arana Therapeutics Chairman, Robin Beaumont said "We are sorry to lose a
director of Greg's calibre and experience. It is unfortunate that he was not
able to continue with his role at Arana, however we wish him well in his new
career path."


"We thank Greg for his contribution to Arana. The company is now well positioned
with a strong financial position, our lead product, ART621 is entering Phase II
trials in 2008 and we have a diverse product pipeline. Greg has significantly
contributed to getting Arana to this position." he added.


About Arana Therapeutics:


Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical
company formed through the merger of Peptech and EvoGenix in August 2007. The
company uses superior technology to develop next generation drugs that will
improve the lives of patients with inflammatory diseases and cancer.


Arana Therapeutics' innovative technologies provide the basis for clinical
development in the antibody space, a market which draws on high demand. With a
market capitalisation of around A$250 million and solid cash resources, Arana
Therapeutics has the financial stability and management expertise to accelerate
its clinical programs, and is on track to have at least 3 clinical stage assets
within three years.


Arana is listed on the Australian Securities Exchange (ASX) and the London Stock
Exchange (AIM).


The company's pipeline consists of four lead drug programs: ART621 to treat
severe rheumatoid arthritis and other inflammatory diseases; ART010 to treat
osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal
cancer; and ART150 for lung cancer and melanoma. Additionally, the company has
earlier stage products in development for the treatment of a range of conditions
including age related macular degeneration, psoriasis, colorectal cancer, and
leukaemia.


Arana has recurring revenues from commercial and development partnerships with
six international companies including GSK, CSL, Centocor (J&J) and Abbott
Laboratories.



For further information: www.arana.com



For further information, please contact:

Arana Therapeutics Ltd
Dr John Chiplin, Chief Executive Officer              +61 (0)2 9870 8788
Niall Henderson, Chief Financial Officer              +61 (0)2 9870 8788

Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com)                 +44 (0)20 7466 5000
Rebecca Skye Dietrich / Catherine Breen

Nomura Code Securities
Charles Walker                                        +44 (0)20 7776 1206














                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAUAUKRBNRUARA
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Arana Therap. Charts.
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Arana Therap. Charts.